Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiora Pharmaceuticals (KPRX) EBITDA (2016 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed EBITDA for 11 consecutive years, with $28867.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA rose 100.89% year-over-year to $28867.0, compared with a TTM value of -$8.7 million through Sep 2025, down 251.74%, and an annual FY2024 reading of $3.5 million, up 127.93% over the prior year.
  • EBITDA was $28867.0 for Q3 2025 at Kiora Pharmaceuticals, up from -$2.1 million in the prior quarter.
  • Across five years, EBITDA topped out at $13.4 million in Q1 2024 and bottomed at -$5.8 million in Q3 2023.
  • Average EBITDA over 5 years is -$2.1 million, with a median of -$2.6 million recorded in 2022.
  • The sharpest move saw EBITDA plummeted 341.61% in 2021, then soared 803.32% in 2024.
  • Year by year, EBITDA stood at -$5.8 million in 2021, then increased by 10.77% to -$5.2 million in 2022, then surged by 57.63% to -$2.2 million in 2023, then plummeted by 102.74% to -$4.4 million in 2024, then surged by 100.65% to $28867.0 in 2025.
  • Business Quant data shows EBITDA for KPRX at $28867.0 in Q3 2025, -$2.1 million in Q2 2025, and -$2.2 million in Q1 2025.